OmniAb Inc. (OABI) - Net Assets
Based on the latest financial reports, OmniAb Inc. (OABI) has net assets worth $277.44 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($309.69 Million) and total liabilities ($32.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check OmniAb Inc. (OABI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $277.44 Million |
| % of Total Assets | 89.59% |
| Annual Growth Rate | 5.68% |
| 5-Year Change | 22.11% |
| 10-Year Change | N/A |
| Growth Volatility | 20.09 |
OmniAb Inc. - Net Assets Trend (2019–2024)
This chart illustrates how OmniAb Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore OABI total asset value for the complete picture of this company's asset base.
Annual Net Assets for OmniAb Inc. (2019–2024)
The table below shows the annual net assets of OmniAb Inc. from 2019 to 2024. For live valuation and market cap data, see market value of OmniAb Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $287.62 Million | -8.57% |
| 2023-12-31 | $314.58 Million | -7.85% |
| 2022-12-31 | $341.37 Million | +45.69% |
| 2021-12-31 | $234.31 Million | -0.52% |
| 2020-12-31 | $235.54 Million | +7.95% |
| 2019-12-31 | $218.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OmniAb Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10140000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.00% |
| Other Comprehensive Income | $27.00K | 0.01% |
| Other Components | $388.98 Million | 135.24% |
| Total Equity | $287.62 Million | 100.00% |
OmniAb Inc. Competitors by Market Cap
The table below lists competitors of OmniAb Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Southern Cross Media Group Ltd
AU:SXL
|
$201.57 Million |
|
HealWELL AI Inc.
TO:AIDX
|
$201.58 Million |
|
cBrain A/S
CO:CBRAIN
|
$201.70 Million |
|
Horizon Technology Finance
NASDAQ:HRZN
|
$201.74 Million |
|
Kore Potash Plc
AU:KP2
|
$201.43 Million |
|
Biomm S.A
SA:BIOM3
|
$201.38 Million |
|
Arqit Quantum Inc.
NASDAQ:ARQQ
|
$201.28 Million |
|
C&C International Corp.
KQ:352480
|
$201.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OmniAb Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 314,585,000 to 287,618,000, a change of -26,967,000 (-8.6%).
- Net loss of 62,033,000 reduced equity.
- New share issuances of 11,369,000 increased equity.
- Other comprehensive income decreased equity by 23,000.
- Other factors increased equity by 23,720,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-62.03 Million | -21.57% |
| Share Issuances | $11.37 Million | +3.95% |
| Other Comprehensive Income | $-23.00K | -0.01% |
| Other Changes | $23.72 Million | +8.25% |
| Total Change | $- | -8.57% |
Book Value vs Market Value Analysis
This analysis compares OmniAb Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.74x to 0.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.90 | $1.40 | x |
| 2020-12-31 | $2.05 | $1.40 | x |
| 2021-12-31 | $2.04 | $1.40 | x |
| 2022-12-31 | $4.00 | $1.40 | x |
| 2023-12-31 | $3.16 | $1.40 | x |
| 2024-12-31 | $2.81 | $1.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OmniAb Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -235.05%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.13x
- Recent ROE (-21.57%) is below the historical average (-11.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -6.23% | -74.18% | 0.07x | 1.20x | $-35.41 Million |
| 2020 | -7.45% | -75.46% | 0.08x | 1.25x | $-41.11 Million |
| 2021 | -11.54% | -77.82% | 0.11x | 1.30x | $-50.47 Million |
| 2022 | -6.54% | -37.80% | 0.14x | 1.23x | $-56.47 Million |
| 2023 | -16.09% | -148.16% | 0.09x | 1.19x | $-82.08 Million |
| 2024 | -21.57% | -235.05% | 0.08x | 1.13x | $-90.79 Million |
Industry Comparison
This section compares OmniAb Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OmniAb Inc. (OABI) | $277.44 Million | -6.23% | 0.12x | $201.54 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more